Rampart Bioscience raises $125M for non-viral gene therapiesnews2023-10-24T11:00:54+00:00October 24th, 2023|Endpoints News|
Aiolos Bio launches with $245M Series A, chasing one of asthma’s hottest targetsnews2023-10-24T11:00:04+00:00October 24th, 2023|Endpoints News|
Heard at #ESMO23: Reflections on ADCs; Novartis and BeiGene falloutnews2023-10-24T10:30:32+00:00October 24th, 2023|Endpoints News|
Sanofi and Regeneron’s anti-inflammatory Dupixent rejected by FDA for chronic hives conditionnews2023-10-23T18:29:27+00:00October 23rd, 2023|Endpoints News|
FDA approves first subcutaneous version of blockbuster IBD drug infliximabnews2023-10-23T18:18:19+00:00October 23rd, 2023|Endpoints News|
Roche dishes out $7.1B for Roivant-Pfizer IBD drug in anti-TL1A sprintnews2023-10-23T06:54:12+00:00October 23rd, 2023|Endpoints News|
Roche details Alecensa data that may shift the drug to postsurgery ALK-positive lung cancer: #ESMO23news2023-10-23T06:21:10+00:00October 23rd, 2023|Endpoints News|
Padcev-Keytruda combo sets new standard of care in bladder cancer at ESMOnews2023-10-23T05:30:25+00:00October 23rd, 2023|Endpoints News|
CARGO Therapeutics files for IPO, aiming to raise money to fund cell therapy ambitionsnews2023-10-21T12:38:47+00:00October 21st, 2023|Endpoints News|
Icahn lawsuit asks for millions in damages, removal of Illumina board membersnews2023-10-21T12:20:50+00:00October 21st, 2023|Endpoints News|
